The wave of securities class actions alleging market manipulation involving recently public, low-float companies continues to grow. Notably, many of these lawsuits have involved non-U.S. companies that recently completed IPOs on U.S. exchanges. Two new pump-and-dump lawsuits, filed within a day of one another in the Southern District of New York against China-based iTonic Holdings Ltd. and Park Ha Biological Technology Co., Ltd., increase the number of market manipulation cases filed in 2026 to 13.
The two complaints present a similar, and familiar, fact pattern. Both companies are China-based operating businesses organized through Cayman Islands holding companies that completed small IPOs on U.S. exchanges at $4 per share and maintained highly concentrated insider ownership following their offerings. In each instance, the company’s share price rose sharply without any corresponding business developments before plunging by more than 90% in a single trading session. The complaints allege that the run-ups were fueled by social media campaigns in which imposters masquerading as investment professionals and promoted fictitious relationships with well-known companies.
As discussed in more detail below, the allegations not only reflect the recurring fact pattern underlying these low-float stock-manipulation cases. but could also provide important insights for D&O underwriters evaluating the risks associated with low-float offerings.
A copy of the complaint against iTonic can be found here. A copy of the complaint against Park Ha can be found here.
The iTonic SCA
iTonic Holdings Ltd., formerly known as Pheton Holdings Ltd., is a Cayman Islands holding company that operates through a Beijing-based subsidiary developing cancer-radiation treatment planning software.
On July 29, 2026, investors filed a securities class action lawsuit against the company, certain directors and officers, its auditor, and its IPO underwriters (the iTonic SCA). The complaint alleges that Pheton’s September 2024 IPO raised approximately $9 million through the sale of 2.25 million shares at $4 per share, while insiders retained most outstanding shares. The company’s stock subsequently climbed to an intraday high of $32 on July 28, 2025, despite the absence of material business developments.
Plaintiffs allege that the increase was fueled by an online promotion campaign in which individuals posing as financial advisors circulated false claims, including fabricated reports that U.S.-based biopharmaceutical company Gilead Sciences was considering an acquisition of, or partnership with, the company.
On July 29, 2025, the alleged scheme unraveled after The Bear Cave published a report questioning the stock’s dramatic appreciation and comparing it to other purported pump-and-dump schemes involving Chinese microcap issuers. Following multiple volatility-related trading halts, the company’s shares fell approximately 95%, from a prior closing price of $30.96 to $1.65. Several days later, on August 1, 2025, the company denied any involvement in stock-price manipulation and stated that the purported Gilead transaction reports were false.
The plaintiffs contend that the defendants failed to disclose the alleged promotion scheme, the company’s susceptibility to stock-price manipulation, and the purported involvement of the auditor and underwriters in other foreign microcap IPOs exhibiting similar trading patterns. The iTonic SCA asserts claims under the Securities Act of 1933, the Securities Exchange Act of 1934, and Rule 10b-5.
The Park Ha SCA
Park Ha Biological Technology (Park Ha) is a Cayman Islands holding company with operations in China that develops and sells skincare and cosmetic products under the Park Ha brand and operates a network of franchise beauty stores.
On July 28, 2026, investors filed their securities class action lawsuit against Park Ha, its controlling shareholder, certain directors and officers, its auditor, and its IPO underwriters (Park Ha SCA). According to the complaint, the company completed its IPO in December 2024, selling 1.2 million shares at $4 per share and raising approximately $4.8 million. The offering allegedly represented less than 5% of the company’s outstanding shares, leaving insiders with more than 95% ownership.
The complaint alleges that Park Ha’s share price rose from its $4 IPO price to an intraday high of $41.49 on July 7, 2025, despite the absence of material corporate developments that would justify the increase. Shareholder plaintiffs allege that individuals using the stolen identities of legitimate financial advisors directed investors from social media advertisements into WhatsApp groups, where they promoted Park Ha shares and falsely claimed that the company was preparing to announce a partnership with L’Oréal, one of the world’s largest beauty and cosmetics companies. The purported advisors allegedly projected returns of between 200% and 300%.
On July 8, 2025, the company’s shares fell approximately 93%, from a prior closing price of $41.01 to $2.99, erasing nearly $1 billion in market capitalization in a single trading session. The plaintiffs allege that the defendants failed to disclose the purported promotion campaign, the artificial trading activity allegedly driving the share price, and the risks associated with the company’s extremely limited public float. The complaint further contends that the IPO was structured in a manner that facilitated the alleged manipulation scheme and asserts claims under the Securities Act of 1933, the Securities Exchange Act of 1934, and Rule 10b-5.
Discussion
The iTonic and Park Ha complaints fit within a growing body of securities litigation involving low-float issuers and underscore several themes of interest to D&O underwriters, including stock-promotion risks and potential liability for offering gatekeepers. Both actions also follow a fact pattern that has become increasingly familiar in recent market-manipulation-related securities lawsuits, many of which involve non-U.S. companies, frequently China-based companies, that recently completed IPOs on U.S. exchanges.
The iTonic and Park Ha lawsuits closely resemble the actions previously filed against Charming Medical, PomDoctor, China Liberal Education Holdings, and Picard Medical. Significantly, these cases also appear to share another common characteristic: they involve foreign issuers, many are China-based companies or issuers with substantial operations in China, that accessed U.S. capital markets through relatively small IPOs. In each case, plaintiffs allege a familiar pattern: a low-float IPO with concentrated insider ownership, a dramatic stock-price increase unsupported by company-specific developments, extensive social-media promotion directed at retail investors, and an eventual collapse that wiped out most of the company’s market value.
Another notable feature of the iTonic and Park Ha SCAs is the increasingly standardized nature of the alleged promotion campaigns. According to both complaints, social-media advertisements directed investors to WhatsApp groups where individuals posing as investment professionals promoted the stocks. A new feature of both lawsuits is the allegation that the companies were purportedly planning partnerships with well-known Western companies. In the iTonic case, the alleged rumors involved Gilead Sciences, while the Park Ha complaint centers on claims of a potential relationship with L’Oréal.
As in many of the earlier low-float cases, the central challenge for plaintiffs will be connecting the alleged conduct of unidentified third-party promoters to the issuer, its executives, and other offering participants. The complaints seek to bridge that gap by alleging that the offerings were structured in a manner that enabled manipulation or that the defendants failed to disclose known risks associated with the companies’ limited public floats and susceptibility to promotional activity. The suits also name the companies’ underwriters and auditors as defendants, reflecting plaintiffs’ continued efforts to extend liability beyond the issuers themselves.
For D&O underwriters, the growing number of pump-and-dump securities suits may reinforce the importance of evaluating low-float structures, concentrated ownership, and controls designed to detect unusual trading activity and online stock promotion. The recent cases also suggest that underwriters should pay particular attention to foreign issuers seeking to access U.S. capital markets through small public offerings, especially where insiders retain overwhelming control following the IPO.
To the extent that a substantial number of these cases involve China-based companies listing on U.S. exchanges, that characteristic may also warrant heightened scrutiny as part of the underwriting process. Whether these allegations ultimately prove sufficient to establish issuer or gatekeeper liability remains to be seen, but the continued filing of similar lawsuits suggests that low-float IPOs may become a significant area of emerging D&O risk.
Recent Comments